ADVIL COLD & FLU TABLET

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

DIPHENHYDRAMINE CITRATE; IBUPROFEN

Tilgjengelig fra:

GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC

ATC-kode:

M01AE51

INN (International Name):

IBUPROFEN, COMBINATIONS

Dosering :

38MG; 200MG

Legemiddelform:

TABLET

Sammensetning:

DIPHENHYDRAMINE CITRATE 38MG; IBUPROFEN 200MG

Administreringsrute:

ORAL

Enheter i pakken:

2/10/20/40/72/80/180

Resept typen:

OTC

Terapeutisk område:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Produkt oppsummering:

Active ingredient group (AIG) number: 0252877001; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2011-02-24

Preparatomtale

_ _
_GlaxoSmithKline Consumer Healthcare Inc. _
_Page 1 of 51_
PRODUCT MONOGRAPH
_ _
ADVIL COLD & FLU
ADVIL PAIN & HEAD COLD NIGHT
Ibuprofen and Diphenhydramine Citrate Caplets
200 mg/38 mg
Analgesic/Antipyretic and Antihistamine
GlaxoSmithKline Consumer Healthcare Inc.
7333 Mississauga Road
Mississauga, Ontario
Canada L5N 6L4
Date of Revision:
June 5, 2020
Submission Control No.: 239352
_ _
_GlaxoSmithKline Consumer Healthcare Inc. _
_Page 2 of 51_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
ADVERSE REACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................22
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL PHARMACOLOGY
............................................................24
STORAGE AND STABILITY
..........................................................................................28
SPECIAL HANDLING INSTRUCTIONS
.......................................................................28
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................28
PART II: SCIENTIFIC INFORMATION
...............................................................................29
PHARMACEUTICAL INFORMATION
..........................................................................29
CLINICAL TRIALS
..........................................................................................................31
DETAILED PHARMACOLOGY
...........................